NSF award 2537891 · NEW England Hemolytics, INC.

SBIR Phase II: Rapid Sepsis Screening System Based on Pathogen DNA Extraction

Final report due

28 November 2028

in 772 days · The award ends on 31 July 2028.

GrantClerk is a private service. We are not NSF or any government agency.

Dates this award owes

NSF emails you about this too.

Decide about an extension2 Apr 2028in 532 days
award ending 2028-07-31 · Research.gov
This one is ours, not NSF’s.
Extension request16 Jun 2028in 607 days
award ending 2028-07-31 · Research.gov
PAPPG 24-1: “at least 45 days prior to the end date”
No-cost extension notice21 Jul 2028in 642 days
award ending 2028-07-31 · Research.gov
PAPPG 24-1: “at least ten calendar days prior to the end date”
Final report due28 Nov 2028in 772 days
award ending 2028-07-31 · Research.gov
PAPPG 24-1: “no later than 120-days following the end date of the award”
Project outcomes report due28 Nov 2028in 772 days
award ending 2028-07-31 · Research.gov
PAPPG 24-1: “no later than 120 days following the end date”
Award is closed out28 Nov 2028in 772 days
award ending 2028-07-31 · Research.gov
PAPPG 24-1: “financially closed out 120 days after their expiration date”

Annual report dates come from the budget period on your award notice. That date is not public, so it is not shown here.

How we got this date

NSF lists this award's end date as 31 July 2028.
NSF rules say the final report is due no later than 120 days after that.
So the final report is due by 28 November 2028.

Read the rule on Research.gov

Get a note before each report date

Add this award to your desk. We email you before each date and keep the dates in one place.

Renews each year until you cancel. Cancel any time from your account.

Already a member? Sign in

Award card

Award number: 2537891
Period of support: 1 Aug 2026 – 31 Jul 2028
Amount: $1,249,902
Awardee: NEW England Hemolytics, INC., Branford, CT
Program: SBIR Phase II
Directorate: TIP

Abstract

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project will be to reduce the time that it takes to identify positive sepsis patients. The type of sepsis-causing pathogen will also be determined by this test, which will aid in guiding correct antibiotic treatment. The device under development is expected to reduce the need for cultures by directly testing a…

Is this right?

We copy this from the public NSF award record. Your award notice and NSF always win. If a date looks wrong, check Research.gov.